Immune checkpoint inhibitors are now at the center of the clinical treatment of metastatic non-small-cell lung cancer (NSCLC). In 2017, the European Commission granted successive approvals to three immune checkpoint inhibitors for bladder cancer: Opdivo, Keytruda, and Tecentriq. In the same year, label expansions were granted to Opdivo for squamous cell carcinoma of the head and neck (SCCHN) and to Tecentriq for NSCLC. As premium-priced immune checkpoint inhibitors enter novel indications and patient populations, payer-imposed reimbursement restrictions and cost-containment strategies will increasingly play a pivotal role in shaping medical oncologists’ prescribing practices and, in turn, determining the commercial success of immune checkpoint inhibitors.
What are the key driving forces and constraints that influence EU5 payers’ reimbursement decisions for immune checkpoint inhibitors in NSCLC, bladder cancer, and SCCHN?
How do market access and reimbursement policies at the national, regional, and local level shape prescribing preferences for immune checkpoint inhibitors?
How do payers prioritize diminishing budgets and control prescribing of immune checkpoint inhibitors?
How do oncologists view emerging immune checkpoint inhibitors, and do they expect to prescribe them? To what extent will EU5 payer policy likely impact the uptake of these novel agents?
Access & Reimbursement reports provide in-depth insight regarding the impact of payer policies on physician prescribing behavior so that clients can build their market access strategy and optimize their brand positioning.
Actionable recommendations to optimize market access, market access success and stumbles, market access roadblocks, reimbursement dynamics, the impact of pricing and reimbursement, policy, and coverage on prescribing.
Scope of Report:
Geography: France, Germany, Italy, Spain, and the United Kingdom (i.e., EU5).
Primary research: Survey of 250 medical oncologists in the EU5 (50 per country) and interviews with 10 EU5 payers (2 per country).